help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on October 28, 2009
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-0550
This Article
Right arrow Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Hollander, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollander, P.

Submitted on March 12, 2009
Accepted on September 2, 2009

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone

Priscilla Hollander*, Jia Li, Elsie Allen, Roland Chen, and for the CV181-013 Investigators

Baylor University Medical Center (P.H.), Dallas, Texas 75246; and Bristol-Myers Squibb (J.L., E.A., R.C.), Princeton, New Jersey 08543

* To whom correspondence should be addressed. E-mail: priscilh{at}BaylorHealth.edu.

Context: Due to the natural progression of type 2 diabetes (T2D), most patients require combination therapy to maintain glycemic control.

Objective: Our objective was to evaluate efficacy and safety of saxagliptin plus thiazolidinedione (TZD) in patients with T2D and inadequate glycemic control on TZD monotherapy.

Design: The study was a multicenter, randomized, double-blind, placebo (PBO)-controlled phase 3 trial conducted from March 13, 2006, to October 15, 2007.

Setting: Patients were recruited from 172 outpatient centers.

Patients: Patients with inadequately controlled T2D [glycosylated hemoglobin (HbA1c) 7.0–10.5%], 18–77 yr, receiving stable TZD monotherapy (pioglitazone 30 or 45 mg or rosiglitazone 4 or 8 mg) for at least 12 wk before screening were eligible.

Interventions: A total of 565 patients were randomized and treated with saxagliptin (2.5 or 5 mg) or PBO, once daily, plus stable TZD dose for 24 wk.

Main Outcome Measures: Primary outcome was change in HbA1c from baseline to wk 24. Secondary outcomes were change from baseline to wk 24 in fasting plasma glucose, proportion of patients achieving HbA1c less than 7.0%, and postprandial glucose area under the curve.

Results: At 24 wk, saxagliptin (2.5 and 5 mg) plus TZD demonstrated statistically significant adjusted mean decreases vs. PBO in HbA1c [-0.66% (P = 0.0007) and -0.94% (P < 0.0001) vs.-0.30%] and fasting plasma glucose [-0.8 mmol/liter (P = 0.0053) and -1 mmol/liter (P = 0.0005) vs.-0.2 mmol/liter]. Proportion of patients achieving HbA1c less than 7.0% was greater for saxagliptin (2.5 and 5 mg) plus TZD vs. PBO [42.2% (P = 0.001) and 41.8% (P = 0.0013) vs. 25.6%]. Postprandial glucose area under the curve was significantly reduced [-436 mmol |b1 min/liter (saxagliptin 2.5 mg plus TZD) and -514 mmol |b1 min/liter (saxagliptin 5 mg plus TZD) vs. -149 mmol |b1 min/liter (PBO)]. Saxagliptin was generally well tolerated; adverse event occurrence and reported hypoglycemic events were similar across all groups.

Conclusions: Saxagliptin added to TZD provided statistically significant improvements in key parameters of glycemic control vs. TZD monotherapy and was generally well tolerated.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society